张卫霞,闫飞艳,白小英,杨 婷,陈 娜.多西紫杉醇联合卡铂治疗老年子宫内膜癌的疗效及安全性[J].现代生物医学进展英文版,2017,17(17):3343-3346. |
多西紫杉醇联合卡铂治疗老年子宫内膜癌的疗效及安全性 |
Clinical Effect and Safety of Docetaxel Combined with Carboplatin in Treatment of Elderly Patients with Endometrial Cancer |
Received:August 31, 2016 Revised:September 25, 2016 |
DOI:10.13241/j.cnki.pmb.2017.17.036 |
中文关键词: 子宫内膜癌 老年患者 多西紫杉醇 卡铂 |
英文关键词: Endometrial cancer Elderly Docetaxel Carboplatin |
基金项目: |
|
Hits: 392 |
Download times: 199 |
中文摘要: |
摘要 目的:探讨多西紫杉醇与卡铂联合化疗在老年子宫内膜癌患者中的疗效及安全性。方法:选择2010年1月至2016年1月我院收治的子宫内膜癌患者78例作为研究对象,其中年龄<60岁的患者42例纳入非老年组,年龄≥60岁的患者36例纳入老年组,均给予多西紫杉醇与卡铂联合化疗。对两组患者一般情况、化疗实施情况、临床疗效以及毒副反应进行观察与比较。结果:两组患者组织学分型有明显差异(P<0.05),其他一般资料无显著差别(P>0.05)。老年组患者采用低剂量完成化疗的比例明显高于非老年组,差异有统计学意义(P<0.05),化疗周期及中断率无显著差异(P>0.05)。两组患者临床疗效、血液系统毒副反应及消化系统毒副反应发生率均差异不显著(P>0.05)。结论:多西紫杉醇与卡铂联合化疗在老年子宫内膜癌患者中治疗效果与非老年患者类似,安全性尚可,值得临床推广应用。 |
英文摘要: |
ABSTRACT Objective: To explore the clinical effect and safety of docetaxel combined carboplatin in treatment of elderly patients with endometrial cancer. Methods: 78 patients with endometrial cancer accepted in our hospital from January 2010 to January 2016 were selected. 42 patients with age <60 were admitted into non-elderly group, and 36 patients with age >60 were considered as elderly group. All the patients were given docetaxel combined carboplatin. Then the general situation, chemotherapy implementation, clinical effect and toxicity reactions of two groups were observed and compared. Results: The histologic classification of two groups had significantly dif- ference (P<0.05), but other general situations had no statistical difference (P>0.05). The patients using low dose in chemotherapy of el- derly group were much more than that of non-elderly group with statistically significance (P<0.05), but the period and interruption rate of two groups had no statistical difference (P>0.05). The clinical effect and the rate of toxicity reactions of two groups had no statistical dif- ference (P>0.05). Conclusion: Using docetaxel combined with carboplatin for elderly patients with endometrial cancer is as effective as non-elderly patients with good safety, worth of clinical applications. |
View Full Text
View/Add Comment Download reader |
Close |